Acrometa Achieves Record Revenue of S$69.5 Million for FY2023, Expanding in Co-Working Lab Space Business

SINGAPORE, Nov 29, 2023 -⁢ (ACN Newswire) – ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with⁢ its⁣ subsidiaries, the “Group”), an established specialist engineering service provider in the field‍ of controlled environments serving mainly the healthcare,‍ biotechnology, pharmaceutical, research and academia sectors, today announced its financial results for the 12 months‌ ended 30 September 2023 (“FY2023”).

Excitingly,‍ the Group’s revenue for FY2023 saw a 12% increase to S$69.5 million, a historical high for the Group, primarily attributed to the Engineering,​ Procurement and Construction⁣ (“EPC”) segment’s strong performance. Gross profit increased by 19% ⁤from S$9.8 million for FY2022 to⁢ S$11.7 million for FY2023, while gross profit ‍margins improved from 15.7%‌ for FY2022 to 16.8% in FY2023.

Despite a challenging operating environment, the Group’s continuing operations comprising of its⁣ specialist EPC and ‌maintenance segments recorded a profit of ‌S$2.2 million on ⁤the back of a 10.8% growth in revenue from S$62.3 million for FY2022 to S$69.0 million for FY2023.

Excitingly, in May 2023, the Group ventured into the co-working laboratory space segment through the‍ acquisition of Life Science Incubator‍ Pte Ltd (“LSI”), which currently manages a 6,500 sqft co-working laboratory space at The German Centre, Singapore. Under the Group’s ⁢leadership, LSI has made significant inroads with new partnerships across Singapore, Australia, and China for new co-working laboratory space ‍projects, reflecting ⁣the ⁣Group’s continued efforts to broaden its revenue stream and capture new ​regional opportunities.

Mr Levin Lee Keng Weng,‍ ACROMETA’s Executive Chairman, said,

“We will continue our current ⁢focus on expanding the laboratory construction and co-working laboratory space businesses, both ‍of⁤ which⁤ are currently cash flow positive with promising long-term prospects amidst an encouraging​ flow of business opportunities‌ and projects in the last twelve​ months.”

The Group’s co-working laboratory space segment contributed positively to AcroMeta’s FY2023 results and will be developed as a⁤ new engine of growth for the Group’s business moving forward.

While the Group’s continuing operations ⁢delivered a profit of S$2.2 ‌million, the Group reported a net loss ‍attributable‍ to owners of S$7.5 million in FY2023 due to the one-off impairment and provisions. Excluding these, the‌ net profit would be S$2.3‌ million compared to FY2022 net profit⁢ of S$2.9 million.

The one-off impairment and‌ provisions relating to discontinuing operations related to renewable energy business are based on historical expenditure and have minimal impact on the Group’s ongoing cashflow. The Group’s net asset⁢ value remains positive at​ S$2.6 million or 0.93 cents per share as at 30 September 2023 ‍while the Group’s cash and cash equivalents are⁤ stable at S$4.4 million as at 30 September 2023 as‌ compared⁤ to S$4.1 ‌million​ as ⁢at 30 September 2022. The​ proposed subscription of 12,500,000 shares in the⁢ capital ‍of the Company for S$0.5 million,⁤ announced in ⁢November 2023, is ‍expected to further‍ strengthen the Group’s⁢ financial resources.

While renewable energy business is fundamentally promising,

» …
Read‌ More rnrn

Latest articles

Related articles